1082549-24-3

Basic information

• Product Name: 3-(1-morpholin-4-yl-ethyl)-phenylamine
• Synonyms: 3-(1-morpholin-4-yl-ethyl)-phenylamine
• CAS NO: 1082549-24-3
• Molecular Weight: 206.288
• Mol File: 1082549-24-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-(1-morpholin-4-yl-ethyl)-phenylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1-morpholin-4-yl-ethyl)-phenylamine(1082549-24-3)
• EPA Substance Registry System: 3-(1-morpholin-4-yl-ethyl)-phenylamine(1082549-24-3)

Safety Data

• Hazardous Substances Data: 1082549-24-3(Hazardous Substances Data)

Upstream product

• 34586-27-1 α-methyl-3-nitrobenzyl chloride 
• 5400-78-2 1-(3-nitrophenyl)ethanol 
• 1190371-32-4 4-[1-(3-nitro-phenyl)-ethyl]-morpholine 

Downstream Products

• 1190378-94-9 cyclobutanecarboxylic acid (3-{5-cyclopropyl-2-[3-(1-morpholin-4-yl-ethyl)-phenylamino]-pyrimidin-4-ylamino}-propyl)-amide 

Relevant articles and documents

PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES

A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, formula (I): wherein: R1 is C3-8-cycloalkyl; X is O, NR7 or C3-6-heterocycloalkyl; R2 is aryl, heteroaryl, fused or unfused aryl-C3-6-heterocycloalkyl or fused or unfused heteroaryl-C3-6-heterocycIoalkyl, each of which is optionally substituted by one or more substitutents selected from aryl, heteroaryl, C1-6-alkyl, C3-7-cycloalkyl and a group A, wherein said C1-6-alkyl group is optionally substituted by one or more substituents selected from aryl, heteroaryl, R10 and a group A, said heteroaryl group is optionally substituted by one or more R10 groups; and wherein said C3-6-heterocycloalkyl group optionally contains one or more groups selected from oxygen, sulfur, nitrogen and CO; R3 is C1-6-alkyl optionally substituted by one or more substituents selected from aryl, heteroaryl, -NR4R5, -OR6, -NR7(CO)R6, -NR7(CO)NR4R5, -NR7SO2R6, -NR7COOR7, -CONR4R5, C3-6-heterocycloalkyl and formula (a, b, c): wherein R4-7 and A are as defined in the claims. Further aspects relate to the use of said compounds in the treatment of various therapeutic disorders, and more particularly as inhibitors of one or more kinases.